New drug combo shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT04126525
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 33 times
Summary
This study tests whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can completely eliminate tumors in women with HER2-positive early breast cancer. About 53 women with stage II to III breast cancer will receive the combination for several weeks before their operation. The main goal is to see how many achieve a pathological complete response, meaning no cancer cells remain in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Renji Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.